RVTY Stock Falls Despite the Latest Launch of Automated Instrument

Revvity, Inc. (RVTY) announced the launch of its new IDS i20 analytical random-access platform from EUROIMMUN. Per management, it is expected to enable full automation of chemiluminescence immunoassays (ChLIA).The IDS i20 instrument is equipped with the ability to process up to 140 tests per hour (assay dependent) and is the latest addition to RVTY’s well-established IDS i-device series.The latest product availability is expected to boost Revvity’s Immunodiagnostics product line under the broader Diagnostic ...